Health TrialsbyHealthPanel

LHC-CIDI-5 in Hong Kong

ConditionsMajor Depressive Episode (MDE)Major Depressive Disorder (MDD)Persistent Depressive Disorder (PDD)Suicidal IdeationSuicidal PlanSuicidal AttemptSuicidal GestureNonsuicidal Self-InjuryManic EpisodeHypomanicBipolar I DisorderBipolar Sub DisorderBipolar II DisorderGeneralized Anxiety Disorder (GAD)Intermittent Explosive Disorder (IED)Panic AttackPanic DisorderObsessive-Compulsive Disorder (OCD)Posttraumatic Stress Disorder (PTSD)PCL-SC PTSDPCL-5 PTSDAlcohol Use Disorder (AUD)Substance Use Disorder (SUD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age25+
SponsorThe University of Hong Kong

About this trial

The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). However, retrospective measurements like the CIDI-5 are susceptible to recall bias, especially for the lifetime experience, which can hinder the reporting accuracy with mental disorders.

To mitigate this issue, the life history calendar (LHC) was introduced as an aid to assist respondents in recalling the timing of life events, enhancing the ability of the CIDI-5 to measure the lifetime prevalence of mental disorders. The LHC is a grid structure with columns representing time units and rows representing life domains under study.

In a study conducted in Nepal, combining the CIDI-5 with the LHC resulted in a significant increase in the detection of mental disorders compared to using the CIDI-5 alone. This approach did not lead to an increase in false positives after clinical validation.

This experiment aims to adapt a Hong Kong version of the LHC based on the Nepalese model and evaluate the effectiveness of the LHC-assisted CIDI-5 (LHC-CIDI-5) compared to the CIDI-5 alone in assessing mental disorders.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All household members aged 25 years old and over are randomly sampled from the Census and Statistics Department List of Quarters

Live in the address sampled from the Census and Statistics Department List of Quarters

Reside in Hong Kong for at least six months in the past year

Able to read and communicate in Chinese or English

Disqualifiers

Domestic workers

Trial population

This study is a sub-study of the District Health Profile (DHP), which is a district-level representative descriptive cross-sectional study. In DHP, 1% of households in selected Hong Kong districts will be randomly selected from the Census and Statistics Department's list of quarters, with stratification based on districts and housing types; all persons aged 18 and above in the recruited households will be included and surveyed. For participants who consent to join the DHP study, a sub-sample of 2,500 participants aged 25 or above will be randomly selected and assigned to two groups through a random process. All 2,500 individuals will complete the survey for the DHP study, including the CIDI-5 section. When administering the CIDI-5, one group of 1,250 individuals will be interviewed using only the CIDI-5, while the other group of 1,250 individuals will be interviewed with LHC first, followed by the CIDI-5.

Trial design

Design model

Ecologic or community

Time perspective

Cross-sectional

Treatments tested in this trial

  • CIDI-5

    Diagnostic test

    The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10) . Trained interviewers will administrate selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes.

  • LHC-CIDI-5

    Diagnostic test

    The interviewer will start by asking the respondent's age and significant personal experiences, which is expected to take 15 minutes. Remembering and recording the experiences provide cognitive engagement and information which can further serve as memory cues for respondents in the following screening of CIDI-5. Subsequently, the respondents will proceed to the screening section for CIDI-5 and will refer to the completed calendar from the LHC section when they are asked to report lifetime experience or age-of-onset for mental disorders. Trained interviewers will conduct all interviews in a computer-assisted personal interview. To validate the diagnoses in the LHC-CIDI-5 group, clinical re-interviews for MDD, GAD, and PTSD will be conducted by a trained mental health professional with previous experience using DSM-5.

Treatment groups

2,500 Participants
are divided into 2 treatment groups
Group A: CIDI-51 intervention
Group B: LHC-CIDI-51 intervention

Trial outcomes

Primary outcomes

1

Depression

The main outcomes in this module are the lifetime prevalence of Major Depressive Episode (MDE) and Major Depressive Disorder (MDD)

Time frame
Immediately following intervention or recruitment
2

Persistent Depression

The main outcome in this module is the lifetime prevalence of Persistent Depressive Disorder (PDD)

Time frame
Immediately following intervention or recruitment
3

Self Harm

The main outcomes in this module are the lifetime prevalence of Suicidal Ideation, Suicidal Plan, Suicidal Attempt, Suicidal Gesture, and Nonsuicidal Self-Injury.

Time frame
Immediately following intervention or recruitment
4

High Mood

The main outcomes in this module are the lifetime prevalence of Manic Episode, Hypomanic, Bipolar I Disorder, Bipolar Sub Disorder, and Bipolar II Disorder

Time frame
Immediately following intervention or recruitment

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The University of Hong Kong

Lead sponsor

Source ClinicalTrials.gov
Apply now